SCHEMBL7159999

SCHEMBL7159999

Cc1cc(CC(=O)c2ccc(F)cc2)ccc1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.47
HTT P42858 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NR1H4 Q96RI1 1/20 0.46
NPC1 O15118 4/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 2/20 0.44
MAPT P10636 2/20 0.44
TP53 P04637 1/20 0.44
ALOX15 P16050 1/20 0.44
MAPK1 P28482 1/20 0.44
HSD17B10 Q99714 1/20 0.44
SRD5A2 P31213 3/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
RXRA P19793 1/20 0.42
PTPN1 P18031 1/20 0.42
XBP1 P17861 1/20 0.42
HIF1A Q16665 1/20 0.42
RARB P10826 1/20 0.42
HTR7 P34969 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7169121 0.83 LMNA (0.43) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL15548459 0.83 PTGS1 (0.57) HTTSMN1; SMN2NR1H4RAB9AKDM4E
SCHEMBL30965013 0.79 SRD5A2 (0.57) LMNANR1H4KDM4EMAPTHSD17B10
SCHEMBL7167952 0.79 SRD5A2 (0.62) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL6201900 0.78 RAB9A (0.59) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL31151831 0.77 NPC1 (0.69) LMNAHTTSMN1; SMN2NPC1RAB9A
SCHEMBL11009620 0.77 NR1H4 (0.49) NR1H4SRD5A2RXRARARB
SCHEMBL7164009 0.77 ALDH1A1 (0.44) HTTSMN1; SMN2NR1H4RAB9AMAPT
SCHEMBL543572 0.76 KEAP1 (0.53) LMNAKDM4EHSD17B10RXRAHIF1A
SCHEMBL29728646 0.76 KEAP1 (0.53) LMNAKDM4EHSD17B10RXRAHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6583126-B2 Treating diabetes, obesity, and diabetes-related diseases. MERCK EROSST CANADA & CO. 2003-06-24 US disclosed
EP-1242432-A1 PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA INC. (CA) 2002-09-25 EP disclosed
US-20020052344-A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) MERCK FROSST CANADA LTD. (CA) 2002-05-02 US disclosed
WO-2001046205-A1 PHOSPHONIC ACID DERIVATIVES AS INHIBITORS OF PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) MERCK FROSST CANADA & CO. (CA) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052344-A1 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) PTPRO, PTPRC, PPM1B LMNA 4531/4885HTT 1784/4885SMN1; SMN2 4523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.